DGX Quest Diagnostics

Q3 2025 10-Q

Filed: Oct 21, 2025Period ending Sep 30, 2025

Health Care

Services-Medical LaboratoriesSEC EDGAR

Quest Diagnostics (DGX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 21, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $2.82B for Q3 2025, up 13.1% YoY from $2.49B; DIS revenues $2.76B, up 13.5% YoY from $2.43B
• Operating margin 13.7% vs 13.3% YoY; Operating income $386M, up 16.8% YoY from $330M

+3 more insights

Risk Factors

• No new or changed risk factors since 2024 10-K according to 10-Q filing
• Continued exposure to regulatory risks from healthcare compliance and reimbursement policy changes

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$2.8B

▲ +13.2% YoY▲ +2.0% QoQ

Net Income

$245M

▲ +8.4% YoY▼ -13.1% QoQ

Net Margin

8.7%

▼ -38bp YoY▼ -151bp QoQ

Source: XBRL data from Quest Diagnostics Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Quest Diagnostics

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.